JPWO2023102225A5 - - Google Patents

Info

Publication number
JPWO2023102225A5
JPWO2023102225A5 JP2024532831A JP2024532831A JPWO2023102225A5 JP WO2023102225 A5 JPWO2023102225 A5 JP WO2023102225A5 JP 2024532831 A JP2024532831 A JP 2024532831A JP 2024532831 A JP2024532831 A JP 2024532831A JP WO2023102225 A5 JPWO2023102225 A5 JP WO2023102225A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
linkage
compound
spacer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543214A5 (https=
JP2024543214A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/051713 external-priority patent/WO2023102225A2/en
Publication of JP2024543214A publication Critical patent/JP2024543214A/ja
Publication of JP2024543214A5 publication Critical patent/JP2024543214A5/ja
Publication of JPWO2023102225A5 publication Critical patent/JPWO2023102225A5/ja
Pending legal-status Critical Current

Links

JP2024532831A 2021-12-03 2022-12-02 Ｕｎｃ１３ａ遺伝子転写物のモジュレーターを使用する神経疾患の処置 Pending JP2024543214A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285786P 2021-12-03 2021-12-03
US63/285,786 2021-12-03
US202263350206P 2022-06-08 2022-06-08
US63/350,206 2022-06-08
US202263398987P 2022-08-18 2022-08-18
US63/398,987 2022-08-18
PCT/US2022/051713 WO2023102225A2 (en) 2021-12-03 2022-12-02 Treatment of neurological diseases using modulators of unc13a gene transcripts

Publications (3)

Publication Number Publication Date
JP2024543214A JP2024543214A (ja) 2024-11-19
JP2024543214A5 JP2024543214A5 (https=) 2025-12-10
JPWO2023102225A5 true JPWO2023102225A5 (https=) 2025-12-10

Family

ID=86613080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532831A Pending JP2024543214A (ja) 2021-12-03 2022-12-02 Ｕｎｃ１３ａ遺伝子転写物のモジュレーターを使用する神経疾患の処置

Country Status (16)

Country Link
US (1) US20250051766A1 (https=)
EP (1) EP4441225A4 (https=)
JP (1) JP2024543214A (https=)
KR (1) KR20240129627A9 (https=)
CN (1) CN119790152A (https=)
AU (1) AU2022400851A1 (https=)
CA (1) CA3239482A1 (https=)
CL (1) CL2024001657A1 (https=)
CO (1) CO2024008076A2 (https=)
CR (1) CR20240269A (https=)
DO (1) DOP2024000107A (https=)
IL (1) IL313203A (https=)
JO (1) JOP20240125A1 (https=)
MX (1) MX2024006763A (https=)
PE (1) PE20250677A1 (https=)
WO (1) WO2023102225A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
AU2023356317A1 (en) * 2022-10-05 2025-05-15 Trace Neuroscience, Inc. Unc13a antisense oligonucleotides and uses thereof
WO2024178223A1 (en) * 2023-02-24 2024-08-29 Northwestern University Antisense oligonucleotides for preventing unc13a misplicing
WO2025186619A1 (en) * 2024-03-05 2025-09-12 Takeda Pharmaceutical Company Limited Compositions and methods for splicing modulation of unc13a
WO2025255388A1 (en) * 2024-06-05 2025-12-11 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2026080323A1 (en) 2024-10-09 2026-04-16 Quralis Corporation Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008800A1 (en) * 2001-11-05 2006-01-12 Christian Rosenmund Unc-13 in the modulation of neurotransmission and secretion events
AU2013203395A1 (en) * 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
DK3155101T3 (da) * 2014-06-16 2020-05-04 Univ Johns Hopkins Sammensætninger og fremgangsmåder til ekspression af CRISPR-leder-RNA´er under anvendelse af H1-promotoren
WO2020102472A1 (en) * 2018-11-15 2020-05-22 President And Fellows Of Harvard College Methods and compositions related to targeting ffar2 and ilc3 populations for the treatment of a gastrointestinal disease
AU2022255175A1 (en) * 2021-04-06 2023-11-23 Trace Neuroscience, Inc. Compositions and methods for treating tdp-43 proteinopathy

Similar Documents

Publication Publication Date Title
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JP2013525330A5 (https=)
JP2016522683A5 (https=)
EP3765476B1 (en) Modified oligonucleotides for use in treatment of tauopathies
TWI870557B (zh) 用於調節ｓｍｎ２之化合物及方法
AU2022402929A1 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
IL313205A (en) Microbial consortia
JPWO2023102225A5 (https=)
JPWO2020247419A5 (https=)
JPWO2023102242A5 (https=)
JP2025518487A5 (https=)
JPWO2023102188A5 (https=)
JP2025501682A (ja) 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド
JPWO2021247800A5 (https=)
US20240368591A1 (en) Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
RU2024118442A (ru) Лечение неврологических заболеваний с применением модуляторов транскриптов гена unc13a
HK40121031A (zh) 具有经修饰的主链化学的剪接转换器反义寡核苷酸
IL313204A (en) Methods for the synthesis of factor D complement inhibitors
JPWO2023028575A5 (https=)
RU2025125558A (ru) Способы лечения нарушений нервной системы
RU2021138237A (ru) Олигонуклеотиды и способы применения для лечения неврологических заболеваний
EA053024B1 (ru) Антисмысловые олигонуклеотиды-переключатели сплайсинга с модифицированной химией скелета
TW202540422A (zh) 用於治療與ｕｂｅ３ａ過表現相關之疾患之組合物及方法
WO2026080323A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JP2023137052A (ja) コンドロイチン硫酸生合成を阻害するアンチセンス核酸